DPY19L3

Across TCGA pan-cancer cohorts, DPY19L3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DPY19L3 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher DPY19L3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DPY19L3 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

GBM, CCRCC, and LUAD are the cancer types where DPY19L3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.529	0.274	.004	15	view →
CCRCC	OS	Median	III,IV	1.000	0.321	.022	5	view →
LUAD	DFS	Median	All	0.895	0.968	.009	4	view →
PDAC	OS	Median	III,IV	0.370	0.984	.024	3	view →
UCEC	DFS	Median	All	1.000	0.931	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DPY19L3–GBM (OS)

Open the GBM breakdown →